Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation.
Bendandi M, Rodríguez-Calvillo M, Inogés S, López-Díaz de Cerio A, Pérez-Simón JA, Rodríguez-Caballero A, García-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J, Orfao A. Bendandi M, et al. Among authors: inoges s. Leuk Lymphoma. 2006 Jan;47(1):29-37. doi: 10.1080/10428190500272473. Leuk Lymphoma. 2006. PMID: 16321824 Clinical Trial.
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Herrero-Sánchez MC, Rodríguez-Serrano C, Almeida J, San Segundo L, Inogés S, Santos-Briz Á, García-Briñón J, Corchete LA, San Miguel JF, Del Cañizo C, Blanco B. Herrero-Sánchez MC, et al. Among authors: inoges s. J Hematol Oncol. 2016 Oct 20;9(1):113. doi: 10.1186/s13045-016-0343-5. J Hematol Oncol. 2016. PMID: 27765055 Free PMC article.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Oliver-Caldés A, González-Calle V, Cabañas V, Español-Rego M, Rodríguez-Otero P, Reguera JL, López-Corral L, Martin-Antonio B, Zabaleta A, Inogés S, Varea S, Rosiñol L, López-Díaz de Cerio A, Tovar N, Jiménez R, López-Parra M, Rodríguez-Lobato LG, Sánchez-Salinas A, Olesti E, Calvo-Orteu M, Delgado J, Pérez-Simón JA, Paiva B, Prósper F, Sáez-Peñataro J, Juan M, Moraleda JM, Mateos MV, Pascal M, Urbano-Ispizua A, Fernández de Larrea C. Oliver-Caldés A, et al. Among authors: inoges s. Lancet Oncol. 2023 Aug;24(8):913-924. doi: 10.1016/S1470-2045(23)00222-X. Epub 2023 Jul 3. Lancet Oncol. 2023. PMID: 37414060 Free article.
Feasibility of idiotype vaccination in relapsed B-cell malignancies.
Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M. Inogés S, et al. Haematologica. 2003 Dec;88(12):1438-40. Haematologica. 2003. PMID: 14688006 No abstract available.
74 results